Pacira BioSciences reported third-quarter revenue of $163.9 million and net income of $10.9 million, or $0.23 per share. Adjusted EBITDA was $52.9 million. The company revised its full-year EXPAREL guidance to $535 million to $540 million.
Total revenues of $163.9 million.
Net product sales of $128.7 million for EXPAREL.
Net product sales of $28.8 million for ZILRETTA.
Net product sales of $5.3 million for iovera°.
Pacira revised its full-year EXPAREL guidance and reiterated its full-year financial guidance for ZILRETTA, iovera, Non-GAAP gross margin, Non-GAAP R&D expense, Non-GAAP SG&A expense, and Stock-based compensation.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance